Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Recruiting now
Conditions studied: Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer, Non-small Cell Lung Cancer Stage I
In brief
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Key facts
- Study ID
- NCT02622581
- Run by
- AIO-Studien-gGmbH
- People needed
- 12400
- Starts
- 2015-12-01
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2025-02-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients who meet all of the following criteria are eligible for the project:
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
- Main project (Metatstatic NSCLC):
- Confirmed non-small cell lung cancer (NSCLC)
- Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only"
- Stage IV, or stage IIIB/C (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
- Systemic therapy or best supportive care
- Satellite Stage I/II/III (NSCLC):
- Confirmed non-small cell lung cancer (NSCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
- Stage I, Stage II, stage IIIA, or stage IIIB/C (UICC8)
- Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
- Satellite SCLC
- Confirmed Small cell lung cancer (SCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
- Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
You may not qualify if…
- none
Where it is running
- Pius-Hospital — Oldenburg, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.